О нас

China Resources Zizhu Pharmaceutical имеет линейки продукции, включающие препараты и устройства для репродуктивного здоровья, пероральные препараты, офтальмологические препараты, диабетические препараты, препараты для местной анестезии и химическое сырье. На внутреннем рынке доля экстренных контрацептивов (таблетки левоноргестрела) и препаратов против беременности (таблетки мифепристона) является одной из самых высоких, а таблетки левоноргестрела являются ведущим брендом в продажах лекарств на платформах электронной коммерции O2O в последние годы. Как поставщик левоноргестрела, компания занимает ведущую долю экспортного рынка в Китае, а ее экспорт таблеток мифепристона и мизопростола занимает одно из первых мест в Китае. С корпоративным девизом "Здоровый Китай, хорошая жизнь",China Resources Zizhu Pharmaceutical продолжает инвестировать в исследования и разработки, фокусироваться на научно-технических инновациях, культивировать область репродуктивного здоровья, специальностей и международного бизнеса с профессионализмом и мастерством, стремясь к новой главе скачкообразного развития!

ИСТОРИЯ
< >
1969
1996
2000
2008
2013
2015
2021
2022

1969

Establishment

In the 1960s and 1970s, Beijing No.3 Pharmaceutical Factory, the predecessor of the company initiated the development of 18-methylnorgestrel, a critical API used for contraceptives and became the first national approved manufacturer of this API a year later. The success of this project filled the gap of oral contraceptive API in China, had epoch-making significance, opened a new chapter for China's industry, and won the "National Science Congress Award" in March 1978.

1996

Relocation

To meet the requirements of urban planning, the manufacture site is relocated to current address, No. 27 Chaoyang North Road, Chaoyang District, Beijing, China. The production in the new manufacture site started on 1 March 1996.

2000

Restructuring

Beijing No. 3 Pharmaceutical Factory was restructured into Beijing Zizhu Pharmaceutical Company Limited in 2000, entering a new stage. The restructuring was in accordance with the State Council's policy on debt-to-equity conversion of partial state-owned enterprises, and approved by the State Economic and Trade Commission and the Beijing Municipal Economic Commission.

2008

API production base

The API production base in Qinhuangdao was built in 2008 based on international development strategical need and Beijing industrial development plan, which guarantees the reliability of API sources for company’s finished products.

2013

Joining CR

The company officially changed its name to China Resources Zizhu Pharmaceutical Co., Ltd. and has become a wholly owned subsidiary of China Resources Pharmaceutical Group since then, entering a brand new stage of development.

2015

Takeover of United Pharmaceutical

Beijing United Pharmaceutical completed the resumption of production and related GMP certification under CRZP’s guidance. The Class II new drug Epalrestat API and finished product were successfully marketed, becoming a billion-dollar variety for CRZP and injecting new momentum into the specialty area.

2021

Green Factory Award

CRZP was selected as a National Green Factory during the event organized by the Ministry of Industry and Information Technology, aiming at implementing "Made in China 2025" and "Industrial Green Development Plan", accelerating the construction of green manufacturing system and creating advanced models of green manufacturing enterprises.

2022

Current

Committing to human life and health industry, CRZP develops, manufactures and markets pharmaceuticals and health products revolving around female health, characteristic specialties, APIs and international business.  

Видео

Доказательство

2019.11

2019.11

WHO GMP

Co-package of Mifepristone Tablets and Misoprostol Tablets

2018.12

2018.12

EU GMP

Levonorgestrel API

2018.10

2018.10

EDQM GMP

Levonorgestrel API

2016.10

2016.10

PIC/S GMP

Misoprostol Tablets and Mifepristone (200mg)Tablets

2016.09

2016.09

Mexico COFEPRIS

Misoprostol Tablets

2016.01

2016.01

WHO GMP

Misoprostol Tablets and Mifepristone (200mg)Tablets

2013.09

2013.09

Mexico COFEPRIS

Levonorgestrel,Mifepristone,Ethinyl Estradiol API

2012.05

2012.05

WHO GMP

Levonorgestrel,Mifepristone,Ethinyl Estradiol API